Using breakthrough proprietary and patented technology developed by BioHarvest Ltd, CannaVcell announced the first ever production of Cannabis cells in suspension, with a cannabinoid profile identical to that of the source plant - without the need to grow the plant itself. This represents the successful completion of the development program that commenced in October of 2018 and aimed to prove the feasibility of BioHarvest's previously proven technology for the production of Cannabinoids and other Cannabis derived compounds. The program was successfully completed 4 months ahead of schedule. The goals for this development stage have been exceeded, as CannaVcell went one step beyond production in liquid media (or suspension) at lab-scale, where it demonstrated fully grown trichomes, and stably produced Cannabis cells and cannabinoids in a small scale bioreactor. This achievement marks a turning point in the Cannabis industry as it will enable to commercially produce Cannabis derived active ingredients without the need to grow the plant. BioHarvest's technology platform ensures lower cost of production, contaminate-free, reduced capital expenditure requirements, and most importantly - a consistent contaminate-free product. BioHarvest expects to complete an initial scale-up process, and reach a commercial production capacity of 2 tons/year by year-end 2020. A significantly larger facility is expected to be completed by year-end 2021. The Bioharvest team has successfully developed industrial scale production processes for other (non-Cannabis) plant cells in the past, and has commercially produced and distributed such products. It appears as if all other research groups that have been focusing on Cannabis cell production have only been able to stably grow trichomes and/or produce cannabinoids in solid media. Doing so in suspension brings CannaVcell and BioHarvest one step closer to commercial scale-up.